METHOD OF PRODUCING RECOMBINANT CAPSID PROTEIN OF HEPATITIS E VIRUS Russian patent published in 2021 - IPC C12Q1/68 C12N15/00 

FIELD: biotechnology; genetic engineering.

SUBSTANCE: method of producing recombinant capsid protein of hepatitis E virus (PORF2) and a recombinant vaccine for preventing viral hepatitis E. Capsid protein is obtained by culturing a recombinant Escherichia coli BL21 (DE3)/PORF2 strain containing a synthetic DNA sequence integrated into an expression vector, optimized for expression in bacterial systems and coding amino acid sequence fragment 121 to 671 of position of capsid protein of hepatitis E virus of genotype 3 (PORF2), substitute carrier in amino acid sequence, specific for VGE strains circulating in RF territory (L284P, S324T, Y354H, S357G, I364V, G490N, V492M, S497T, T517S, S527T, F537Y, V571I) under control of hybrid promoter and regulatory sequences of T7 RNA polymerase in self-induction conditions with alpha-lactose. Based on the obtained antigen, a recombinant vaccine for preventing viral hepatitis E is created. Vaccine contains an effective amount of PORF2 protein, an adjuvant and a physiologically acceptable diluent.

EFFECT: method enables to obtain immunogenic hepatitis E virus antigen possessing natural protein properties.

2 cl, 5 ex, 2 dwg